Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma-Reference-Cited by-同舟云学术

Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma

Published:2016-10-17 Issue:4 Volume:180 Page:581-585
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Teramachi Jumpei¹²,Hiasa Masahiro¹³,Oda Asuka¹,Harada Takeshi¹,Nakamura Shingen¹,Amachi Ryota¹⁴,Tenshin Hirofumi¹⁴,Iwasa Masami¹,Fujii Shiro¹,Kagawa Kumiko¹,Miki Hirokazu⁵,Kurahashi Kiyoe¹,Yoshida Sumiko¹,Endo Itsuro¹,Haneji Tatsuji²,Matsumoto Toshio⁶,Abe Masahiro¹

Affiliation:

1. Department of Haematology, Endocrinology and Metabolism; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan

2. Department of Histology and Oral Histology; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan

3. Department of Biomaterials and Bioengineering; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan

4. Department of Orthodontics and Dentofacial Orthopedics; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan

5. Division of Transfusion Medicine and Cell Therapy; Tokushima University Hospital; Tokushima Japan

6. Fujii Memorial Institute of Medical Sciences; Tokushima University; Tokushima Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14388/fullpdf

Reference10 articles.

1. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells;Asano;Leukemia,2011

2. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease;Giuliani;Blood,2002

3. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation;Hammerman;Cancer Research,2004

4. Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma;Hiasa;Leukemia,2015

5. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target;Johrer;Journal of Molecular Medicine,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIM2 Kinase Regulates TIGIT Expression and Function in NK Cells from Multiple Myeloma Patients;2024-02-16

2. An overview of pim kinase as a target in multiple myeloma;Cancer Medicine;2023-05

3. Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors;International Journal of Hematology;2023-04-11

4. Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase;Blood Advances;2023-03-20

5. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents;Journal of Bone and Mineral Metabolism;2023-03-01